Early termination after 68 randomizations reflected a 61% serious AE rate and 19% treatment-related deaths with radiotherapy, ...
In an interview with Targeted Oncology, Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed which ...
Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed the evolving role of measurable residual disease (MRD) as ...
ENDURANCE randomized 516 standard-risk, transplant-deferred patients after PI–lenalidomide induction to indefinite vs 2-year lenalidomide maintenance, powered for a 50% median OS improvement.
Dr. Monty Pal discusses how the increasing use of adjuvant immunotherapy has introduced new considerations for the management ...
In this interview with Targeted Oncology managing editor Sabrina Serani, Estelamari Rodriguez, MD, MPH, hematologist-oncologist at Sylvester Comprehensive Cancer Center, discusses ...
A third CRL was issued for rivoceranib plus camrelizumab in first-line unresectable/metastatic HCC, driven by cGMP ...
Bispecific antibodies have emerged as a transformative class of therapies in multiple myeloma and beyond, but the need for ...
Hansen, MD, discusses outcomes from a large retrospective study of patients treated with ciltacabtagene autoleucel for ...
The first clinical case presents a 58-year-old female never-smoker with persistent cough, mild dyspnea, and new right-sided ...
Pettit, MD, and participants discussed second-line considerations in high-risk polycythemia after hydroxyurea failure.
The panel discusses the full multidisciplinary team required to optimize outcomes for patients with ROS1-positive advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results